The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs

Giuseppe Palasciano, Piero Portincasa, Vincenzo Palmieri, Daniela Ciani, Gianluigi Vendemiale, Emanuele Altomare

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The efficacy of the antioxidant silymarin in preventing psychotropic drug-induced hepatic damage was evaluated in a double-blind, placebo-controlled study. Sixty patients receiving chronic psychotropic drug therapy were randomly divided into four groups and were treated for 90 days with silymarin or placebo as follows: group IA-treatment with psychotropic drugs and silymarin, 800 mg/d; group IB-treatment with psychotropic drugs and placebo; group IIA-suspension of psychotropic drugs plus treatment with silymarin, 800 mg/d; and group IIB-suspension of psychotropic drugs plus treatment with placebo. Serum levels of malon-dialdehyde (the end product of the oxidation of polyunsaturated fatty acids) and the indices of hepatocellular function were assessed in each patient at baseline (day 0), on days 15, 30, 60, and 90, and 1 month after the completion of treatment. Our data show that silymarin, when used at submaximal doses, reduces the lipoperoxidative hepatic damage that occurs during treatment with butyrophenones or phenothiazines. The study results also suggest that increased lipoperoxidation may contribute to psychotropic drug-induced hepatotoxicity.

Original languageEnglish
Pages (from-to)537-545
Number of pages9
JournalCurrent Therapeutic Research
Volume55
Issue number5
DOIs
Publication statusPublished - 1994

Fingerprint

Silymarin
Psychotropic Drugs
Placebos
Therapeutics
Suspensions
Butyrophenones
Phenothiazines
Liver
Unsaturated Fatty Acids
Antioxidants
Drug Therapy
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs. / Palasciano, Giuseppe; Portincasa, Piero; Palmieri, Vincenzo; Ciani, Daniela; Vendemiale, Gianluigi; Altomare, Emanuele.

In: Current Therapeutic Research, Vol. 55, No. 5, 1994, p. 537-545.

Research output: Contribution to journalArticle

Palasciano, Giuseppe ; Portincasa, Piero ; Palmieri, Vincenzo ; Ciani, Daniela ; Vendemiale, Gianluigi ; Altomare, Emanuele. / The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs. In: Current Therapeutic Research. 1994 ; Vol. 55, No. 5. pp. 537-545.
@article{d53f995ac1e8437885a114bc47798851,
title = "The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs",
abstract = "The efficacy of the antioxidant silymarin in preventing psychotropic drug-induced hepatic damage was evaluated in a double-blind, placebo-controlled study. Sixty patients receiving chronic psychotropic drug therapy were randomly divided into four groups and were treated for 90 days with silymarin or placebo as follows: group IA-treatment with psychotropic drugs and silymarin, 800 mg/d; group IB-treatment with psychotropic drugs and placebo; group IIA-suspension of psychotropic drugs plus treatment with silymarin, 800 mg/d; and group IIB-suspension of psychotropic drugs plus treatment with placebo. Serum levels of malon-dialdehyde (the end product of the oxidation of polyunsaturated fatty acids) and the indices of hepatocellular function were assessed in each patient at baseline (day 0), on days 15, 30, 60, and 90, and 1 month after the completion of treatment. Our data show that silymarin, when used at submaximal doses, reduces the lipoperoxidative hepatic damage that occurs during treatment with butyrophenones or phenothiazines. The study results also suggest that increased lipoperoxidation may contribute to psychotropic drug-induced hepatotoxicity.",
author = "Giuseppe Palasciano and Piero Portincasa and Vincenzo Palmieri and Daniela Ciani and Gianluigi Vendemiale and Emanuele Altomare",
year = "1994",
doi = "10.1016/S0011-393X(05)80184-5",
language = "English",
volume = "55",
pages = "537--545",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs

AU - Palasciano, Giuseppe

AU - Portincasa, Piero

AU - Palmieri, Vincenzo

AU - Ciani, Daniela

AU - Vendemiale, Gianluigi

AU - Altomare, Emanuele

PY - 1994

Y1 - 1994

N2 - The efficacy of the antioxidant silymarin in preventing psychotropic drug-induced hepatic damage was evaluated in a double-blind, placebo-controlled study. Sixty patients receiving chronic psychotropic drug therapy were randomly divided into four groups and were treated for 90 days with silymarin or placebo as follows: group IA-treatment with psychotropic drugs and silymarin, 800 mg/d; group IB-treatment with psychotropic drugs and placebo; group IIA-suspension of psychotropic drugs plus treatment with silymarin, 800 mg/d; and group IIB-suspension of psychotropic drugs plus treatment with placebo. Serum levels of malon-dialdehyde (the end product of the oxidation of polyunsaturated fatty acids) and the indices of hepatocellular function were assessed in each patient at baseline (day 0), on days 15, 30, 60, and 90, and 1 month after the completion of treatment. Our data show that silymarin, when used at submaximal doses, reduces the lipoperoxidative hepatic damage that occurs during treatment with butyrophenones or phenothiazines. The study results also suggest that increased lipoperoxidation may contribute to psychotropic drug-induced hepatotoxicity.

AB - The efficacy of the antioxidant silymarin in preventing psychotropic drug-induced hepatic damage was evaluated in a double-blind, placebo-controlled study. Sixty patients receiving chronic psychotropic drug therapy were randomly divided into four groups and were treated for 90 days with silymarin or placebo as follows: group IA-treatment with psychotropic drugs and silymarin, 800 mg/d; group IB-treatment with psychotropic drugs and placebo; group IIA-suspension of psychotropic drugs plus treatment with silymarin, 800 mg/d; and group IIB-suspension of psychotropic drugs plus treatment with placebo. Serum levels of malon-dialdehyde (the end product of the oxidation of polyunsaturated fatty acids) and the indices of hepatocellular function were assessed in each patient at baseline (day 0), on days 15, 30, 60, and 90, and 1 month after the completion of treatment. Our data show that silymarin, when used at submaximal doses, reduces the lipoperoxidative hepatic damage that occurs during treatment with butyrophenones or phenothiazines. The study results also suggest that increased lipoperoxidation may contribute to psychotropic drug-induced hepatotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0028332566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028332566&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(05)80184-5

DO - 10.1016/S0011-393X(05)80184-5

M3 - Article

AN - SCOPUS:0028332566

VL - 55

SP - 537

EP - 545

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -